Sign In
Buy PULM
$1.29
-0.0300 (-2.27%)
At Close: Jun 03, 2026
Pulmatrix Announces First Quarter 2026 Financial Results
09:00am, Friday, 15'th May 2026
Pulmatrix Announces First Quarter 2026 Financial Results PR Newswire FRAMINGHAM, Mass., May 15, 2026
Pulmatrix Announces First Quarter 2026 Financial Results
08:20am, Friday, 15'th May 2026
Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasda
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
08:00am, Tuesday, 21'st Apr 2026
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pu
PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders
09:55am, Monday, 13'th Apr 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Eos SENOLYTIX, Inc. Upon closing of the proposed transaction
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
04:10am, Saturday, 11'th Apr 2026
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report) shares passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $2.15 and traded as low as $1.18. Pulm
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
08:00am, Thursday, 26'th Mar 2026
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related disea
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
08:00am, Monday, 02'nd Mar 2026
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agree
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
08:05am, Thursday, 26'th Feb 2026
Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceu
Pulmatrix (NASDAQ:PULM) Share Price Crosses Below 50 Day Moving Average – What’s Next?
01:42am, Tuesday, 17'th Feb 2026
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $2.71 and traded as low as $2.
INmune Bio (NASDAQ:INMB) & Pulmatrix (NASDAQ:PULM) Head-To-Head Review
01:22am, Friday, 16'th Jan 2026
Pulmatrix (NASDAQ: PULM - Get Free Report) and INmune Bio (NASDAQ: INMB - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on th
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
08:05am, Thursday, 18'th Dec 2025
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass. , Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatr
Pulmatrix (NASDAQ:PULM) Stock Price Passes Below 50-Day Moving Average – Here’s Why
04:14am, Friday, 05'th Dec 2025
Pulmatrix, Inc. (NASDAQ: PULM - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $4.75 and traded as lo
Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets
08:05am, Thursday, 16'th Oct 2025
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecul
Pulmatrix (PULM) Q2 Revenue Falls 100%
09:58pm, Wednesday, 06'th Aug 2025
Pulmatrix (PULM) Q2 Revenue Falls 100%
Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets
08:05am, Wednesday, 06'th Aug 2025
Proposed merger anticipated to close in 2025 As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, whic
